EyePoint Pharmaceuticals Inc (PSDV) - Product Pipeline Analysis, 2018 Update

  • ID: 4439692
  • Company Profile
  • 33 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Akers Biosciences Inc
  • Eli Lilly and Co
  • Radius Health Inc
  • MORE
Summary

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint's iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company EyePoint Pharmaceuticals Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akers Biosciences Inc
  • Eli Lilly and Co
  • Radius Health Inc
  • MORE
EyePoint Pharmaceuticals Inc Company Overview
  • EyePoint Pharmaceuticals Inc Company Snapshot
  • EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview
  • EyePoint Pharmaceuticals Inc – Pipeline Analysis Overview
  • EyePoint Pharmaceuticals Inc - Key Facts
  • EyePoint Pharmaceuticals Inc - Major Products and Services
  • EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage
  • EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status
EyePoint Pharmaceuticals Inc Pipeline Products Overview
  • Durasert - Back Of Eye Disease
  • Durasert - Back Of Eye Disease Product Overview
  • Durasert - Front Of Eye Disease
  • Durasert - Front Of Eye Disease Product Overview
  • Durasert - Knee Osteoarthritis
  • Durasert - Knee Osteoarthritis Product Overview
  • Durasert Latanoprost Implant
  • Durasert Latanoprost Implant Product Overview
  • DURASERT With TKI - Wet AMD
  • DURASERT With TKI - Wet AMD Product Overview
  • Next Gen Duraset - Posterior Segment Uveitis
  • Next Gen Duraset - Posterior Segment Uveitis Product Overview
  • Tethadur System
  • Tethadur System Product Overview
  • YUTIQ
  • YUTIQ Product Overview
  • YUTIQ Clinical Trial
EyePoint Pharmaceuticals Inc - Key Competitors

EyePoint Pharmaceuticals Inc - Key Employees

EyePoint Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
EyePoint Pharmaceuticals Inc, Recent Developments
  • Jul 11, 2018: EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
  • Jul 10, 2018: BioArctic receives regulatory approval in Finland for Phase 1/2 study in patients with Complete Spinal Cord Injury
  • Jun 26, 2018: EyePoint Pharmaceuticals Names Goran Ando As Board Director
  • May 16, 2018: EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
  • May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
  • Apr 18, 2018: EyePoint Pharmaceuticals YUTIQ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  • Mar 19, 2018: pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert Three-Year Treatment for Posterior Segment Uveitis
  • Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
  • Feb 07, 2018: pSivida's Second Phase 3 Study for Durasert Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
  • Jan 08, 2018: pSivida Submits New Drug Application for Durasert Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
Appendix
  • Methodology
  • Contact Us
  • Disclaimer
List of Tables
  • EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview
  • EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type
  • EyePoint Pharmaceuticals Inc Pipeline Products by Indication
  • EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status
  • EyePoint Pharmaceuticals Inc, Key Facts
  • EyePoint Pharmaceuticals Inc, Major Products and Services
  • EyePoint Pharmaceuticals Inc Number of Pipeline Products by Development Stage
  • EyePoint Pharmaceuticals Inc Pipeline Products Summary by Development Stage
  • EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status
  • EyePoint Pharmaceuticals Inc Ongoing Clinical Trials Summary
  • Durasert - Back Of Eye Disease - Product Status
  • Durasert - Back Of Eye Disease - Product Description
  • Durasert - Front Of Eye Disease - Product Status
  • Durasert - Front Of Eye Disease - Product Description
  • Durasert - Knee Osteoarthritis - Product Status
  • Durasert - Knee Osteoarthritis - Product Description
  • Durasert Latanoprost Implant - Product Status
  • Durasert Latanoprost Implant - Product Description
  • DURASERT With TKI - Wet AMD - Product Status
  • DURASERT With TKI - Wet AMD - Product Description
  • Next Gen Duraset - Posterior Segment Uveitis - Product Status
  • Next Gen Duraset - Posterior Segment Uveitis - Product Description
  • Tethadur System - Product Status
  • Tethadur System - Product Description
  • YUTIQ - Product Status
  • YUTIQ - Product Description
  • YUTIQ - A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye
  • YUTIQ - A Phase III, Multi-national, Multi-center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye
  • EyePoint Pharmaceuticals Inc, Key Employees
  • EyePoint Pharmaceuticals Inc, Subsidiaries
  • Glossary
List of Figures
  • EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type
  • EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage
  • EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Radius Health Inc
  • Eli Lilly and Co
  • Akers Biosciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll